{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:27:29Z","timestamp":1793039249567,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.gastrohep.2021.01.007","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T22:40:12Z","timestamp":1614292812000},"page":"587-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Riesgo de infecci\u00f3n asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biol\u00f3gicas en enfermedad inflamatoria intestinal y artritis reumatoide. Estrategias de prevenci\u00f3n"],"prefix":"10.1016","volume":"44","author":[{"given":"Xavier","family":"Calvet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Carpio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Rodr\u00edguez-Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garc\u00eda-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barreiro-de-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Juanola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Aguas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Gratac\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2021.01.007_bib0410","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2015.08.008","article-title":"Vaccinations in adults with chronic inflammatory joint disease: Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs","volume":"83","author":"Morel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0415","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0420","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ecco-jcc\/jjz013","article-title":"Relevant infections in inflammatory bowel disease, their relationship with immunosuppressive therapy and their effects on disease mortality","volume":"25","author":"Zabana","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0425","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: Preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0430","first-page":"431","article-title":"Vaccination of patients with inflammatory bowel disease","volume":"13","author":"Farraye","year":"2017","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0435","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0440","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0445","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1016\/j.vaccine.2018.06.065","article-title":"Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases","volume":"36","author":"Harrison","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0450","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.vaccine.2015.01.065","article-title":"Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the international COMORA cohort","volume":"33","author":"Hmamouchi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0455","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.reuma.2017.06.002","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: The Spanish cohort of the COMORA study","volume":"15","author":"Balsa","year":"2019","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0460","first-page":"1","article-title":"Vaccination in patients with inflammatory bowel diseases","author":"Manser","year":"2020","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0465","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/ibd.21667","article-title":"Vaccinating the inflammatory bowel disease patient: Deficiencies in gastroenterologists knowledge","volume":"17","author":"Wasan","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0470","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12876-017-0602-0","article-title":"Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: A systematic review and network meta-analysis","volume":"17","author":"Wheat","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0475","doi-asserted-by":"crossref","first-page":"ofw205","DOI":"10.1093\/ofid\/ofw205","article-title":"Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis","volume":"3","author":"Marra","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0480","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0485","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0490","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","article-title":"Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases","volume":"17","author":"Beaugerie","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0495","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11894-019-0720-7","article-title":"IBD in the elderly: Management challenges and therapeutic considerations","volume":"21","author":"Tran","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0500","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0505","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy222.025","article-title":"OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: Final results from the GEMINI LTS study","volume":"13","author":"Vermeire","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0510","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0515","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/apt.16119","article-title":"Ustekinumab is effective and safe for ulcerative colitis through 2years of maintenance therapy","volume":"52","author":"Panaccione","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0520","first-page":"30044","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis","volume":"13","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0525","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0530","article-title":"Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the ulcerative colitis clinical programme","author":"Winthrop","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0535","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0540","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0545","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0550","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0555","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: A meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0560","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0565","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 10","key":"10.1016\/j.gastrohep.2021.01.007_bib0570","article-title":"Long-term safety of tofacitinib up to 9.5years: A comprehensive integrated analysis of the RA clinical development program [abstract]","volume":"70","author":"Cohen","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0575","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0580","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0585","doi-asserted-by":"crossref","first-page":"e000546","DOI":"10.1136\/rmdopen-2017-000546","article-title":"Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0590","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/ referral\/xeljanz-h-20-1485-c-4214-0017-assessment-report-article-20_en.pdf. 2020."},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0595","unstructured":"https:\/\/cima.aemps.es\/cima\/dochtml\/ ft\/1171178003\/FT_1171178003.html. 2020."},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0600","article-title":"Effect of IBD medications on COVID-19 outcomes: Results from an international registry","author":"Ungaro","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0605","unstructured":"COVID-19 y enfermedad inflamatoria intestinal: preguntas surgidas de la atenci\u00f3n y seguimiento de los pacientes durante la fase inicial dela pandemia (febrero-abril 2020). https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0210570520301382"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0610","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/gutjnl-2020-321269","article-title":"COVID-19 and immunomodulation in IBD","volume":"69","author":"Neurath","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0615","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jbspin.2020.05.003","article-title":"Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy","volume":"87","author":"Quartuccio","year":"2020","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0620","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry","volume":"159","author":"Brenner","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0625","article-title":"Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD Registry","author":"Agrawal","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0630","first-page":"317","article-title":"Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs","volume":"36","author":"Meroni","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0635","unstructured":"https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/programasDeVacunacion\/riesgo\/home.htm"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0640","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease","volume":"21","author":"Marin","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0645","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs: Practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0655","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0660","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/acr.21838","article-title":"Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis","volume":"65","author":"Ribeiro","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0665","doi-asserted-by":"crossref","first-page":"ofu024","DOI":"10.1093\/ofid\/ofu024","article-title":"Rates of pneumococcal disease in adults with chronic medical conditions","volume":"1","author":"Shea","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0670","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2015.284","article-title":"Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: A nationwide Danish cohort study 1977-2013","volume":"110","author":"Kantso","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0675","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.14309\/ajg.0000000000000289","article-title":"High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease","volume":"114","author":"Pittet","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0680","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0685","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0690","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/ibd\/izy150","article-title":"Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: Mechanism, epidemiology, management, and prevention","volume":"24","author":"Colombel","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0695","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/annrheumdis-2019-eular.1130","article-title":"FRI0164 Incidence rate and characterization of herpes zoster in patients with moderate-to-severe rheumatoid arthritis: An update from baricitinib clinical studies","volume":"78","author":"Chen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0700","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: Clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0705","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0710","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3899\/jrheum.160685","article-title":"longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases","volume":"44","author":"Yun","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0715","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0720","doi-asserted-by":"crossref","first-page":"k4029","DOI":"10.1136\/bmj.k4029","article-title":"Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: Systematic review and network meta-analysis","volume":"363","author":"Tricco","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0725","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40266-018-0603-x","article-title":"Recombinant zoster vaccine (Shingrix\u00ae): A review in herpes zoster","volume":"35","author":"Syed","year":"2018","journal-title":"Drugs Aging"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0730","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0735","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitisB andC in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmii.2017.10.002","article-title":"Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review","volume":"52","author":"Chen","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0745","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitisB virus infection in patients with rheumatoid arthritis receiving tofacitinib: A real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0750","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of hepatitisB reactivation in patients with psoriasis on ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"Suppl 10","key":"10.1016\/j.gastrohep.2021.01.007_bib0755","article-title":"The use of tocilizumab and tofacitinib in patients with resolved hepatitisB infection: A case series [abstract]","volume":"72","author":"Serling-Boyd","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0760","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitisB: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0765","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrgastro.2013.28","article-title":"Vaccination strategies in patients with IBD","volume":"10","author":"Gisbert","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0770","unstructured":"https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-vedolizumab-Entyvio-GCPT.pdf. 2020."},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0775","first-page":"36","article-title":"Consensus document on prevention and treatment of tuberculosis in patients for biological treatment","volume":"52","author":"Mir","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0780","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.20496","article-title":"Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy","volume":"14","author":"Zabana","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0785","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.arbr.2018.04.008","article-title":"Screening for latent tuberculosis infection in patients who are candidate for biological therapies in Spain? A multidisciplinary survey","volume":"54","author":"Quiros","year":"2018","journal-title":"Arch Bronconeumol"},{"issue":"Suppl 2","key":"10.1016\/j.gastrohep.2021.01.007_bib0790","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0795","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/imt-2018-0113","article-title":"Tuberculosis, hepatitisB and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0800","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0805","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14740338.2020.1703946","article-title":"The impact of the interleukin 12\/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis","volume":"19","author":"Zabotti","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.gastrohep.2021.01.007_bib0810","author":"Riestra","year":"2020","journal-title":"Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052100056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052100056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:44:14Z","timestamp":1759322654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057052100056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S021057052100056X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.01.007","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Riesgo de infecci\u00f3n asociado a los inhibidores de las quinasas Janus (JAK) y las terapias biol\u00f3gicas en enfermedad inflamatoria intestinal y artritis reumatoide. Estrategias de prevenci\u00f3n","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}